Drug Profile
Exicorilant - Corcept Therapeutics
Alternative Names: 14C-CORT125281; CORT 125281Latest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator Corcept Therapeutics
- Class Antineoplastics; Fluorinated hydrocarbons; Isoquinolines; Pyrazoles; Pyridines; Small molecules; Sulfones; Triazoles
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 09 Jan 2023 Corcept Therapeutics completes phase-I/II trial in Prostate cancer (Combination therapy, Hormone refractory) in United Kingdom and US (PO) (NCT03437941) (EudraCT2017-003287-12)
- 09 Sep 2022 Pharmacokinetics and adverse events data from a phase I/IIa trial in Prostate cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Prostate-cancer(In volunteers) in United Kingdom (PO, Capsule)